ABSTRACT
Introduction: COVID-19 infection is a disease caused by the type 2 coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) that affects the respiratory mucosa and all those organs that present the type 2 angiotensin receptor (ACE2), within them the skin. Several authors have mentioned the importance of reporting and carrying out databases on skin lesions caused by this virus, since it is related to the detection, severity and prognosis of the systemic condition. Material(s) and Method(s): A retrospective cross-sectional observational study was carried out on the cases of patients who presented dermatological manifestations due to COVID-19, registered in the physical database of the National Specialized Hospital of Villa Nueva, Guatemala, from January 1st to December 31, 2021. Result(s): A total of 144 patients presented dermatological manifestations due to COVID-19, which were: acral lesions (42%), rash (21%), subcutaneous emphysema (12%), oral mucosal lesions (7%), necrosis (6%), erythema multiforme (5%), telogen effluvium (2%), vesicular lesions (2%), urticaria (1%), pityriasis rosea Gibert (1%) and livedo-type lesion (1%). A statistically significant association (p = 0,00) was found in patients who presented dermatological manifestations with vasculonecrotic damage as they were more likely to suffer from severe to critical disease (OR 2,91;95% CI 1063-3083). Conclusion(s): Early identification of cutaneous semiology is essential for timely management of complications associated with COVID-19 disease.Copyright © 2022 Elsevier Espana, S.L.U.
ABSTRACT
Introduction: COVID-19 disease is caused by SARS COV-2 virus. Though it primarily affects the lower respiratory tract, reports have indicated that specific cutaneous manifestations are associated with COVID-19. Objective(s): To evaluate the persistent dermatologic long term sequelae of SARS-CoV-2 infection, among recovered COVID-19 infected patients. Method(s): Baseline data were retrospectively collected from patient's medical records from the department of dermatology over 1 year (January 2021-January 2022), at a designated tertiary care centre. The demographic data, severity of COVID disease, and pre-existing cutaneous and systemic co-morbidities were noted. Dermatologic, hair and nail manifestations were recorded. The results were statistically analyzed. Result(s): Record of total 972 patients were analyzed in our study, with 432 males and 340 females. Out of these, 88 cases (9.05%) had skin manifestations, of which 35 (39.77%) were male, and 53 (60.22%) were females. About 50% of cases experienced long term skin diseases after 6 months of the recovery. The majority, 47 (53.4%) of patients with skin manifestations, were in the age group of 30-50 years, followed by 31 (35.22 %) of patients in the 50 years age and above group. Urticaria and Pruritus were the most common manifestations 26 (29.5%), followed by telogen effluvium 24 (27.7%), herpes zoster 16(18.1%), pityriasis rosea, acneform eruptions, acral erythema, irritant contact dermatitis, palmar keratoderma, aphthous ulcer with lip crackling, eruptive pseudo angiomatosis, aquagenic keratoderma, and others. Conclusion(s): Prevalence of cutaneous, hair and nail manifestations among COVID-19 patients was 88 (9.05%) in our study. More extensive research is required to establish our knowledge on the relation between skin and COVID-19.Copyright © 2023, Dr Yashwant Research Labs Pvt Ltd. All rights reserved.
ABSTRACT
Background: Cutaneous adverse drug reactions (CADRs), also known as toxidermia, are skin manifestations resulting from systemic drug administration and it constituted 10%-30% among all reported adverse drug reactions (ADRs). These reactions range from mild morbilliform drug rash to much more severe reactions. Material(s) and Method(s): A retrospective observational study was conducted at dermatology outpatient department of rural based tertiary care center for a duration of 03 years from August 2019 to July 2022, a total of 211 patients who had been clinically diagnosed or were suspected to have drug reactions were studied. Result(s): In this observation there was male preponderance (59.72%) and majority of patients were in their 3rd and 4th decade (40.28%) with maculopapular drug rash (33.17%) being most common clinical profile of CADRs, followed by urticaria (23.70%). Less frequently seen CADRs were acneiform eruptions (21), hair Loss (9), photodermatitis (9), generalised pruritus (7), erythroderma (2), pityriasis rosea (2), Stevens Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) (4), lichenoid drug eruptions (3), Vasculitis (1) and pustular drug eruption (1). The most common group of drugs causing CADRs were antibiotics (40.28%), followed by NSAIDs (28.43%). Conclusion(s): Cutaneous Adverse Drug Reactions (CADRs) are price we pay for the benefits of modern drug therapy;knowledge of these reactions is important for treating physician as prompt recognition and treatment can prove lifesaving.Copyright © 2022 Academic Medicine and Pharmacy
ABSTRACT
Objective: COVID-19 has been significantly associated with both psychosocial stress and physiologic stress, both of which are known to trigger telogen effluvium. This study was performed to estimate the prevalence of hair loss among patients with COVID-19 and to determine the correlation of the severity of COVID-19 with the severity of hair loss. Method(s): Data were collected through a self-administered electronic questionnaire that was distributed among social media platforms. Participants were invited to complete the survey using a convenience sampling technique. A multiple response dichotomies analysis and chi-square test of independence were used to analyze data. Result(s): Among 420 participants who reported a positive PCR result of SARS-CoV-2, 77.6% reported hair loss after COVID-19 development. Notably, the onset of hair loss was within 3 weeks of COVID-19 development in 29% of participants. Most of the participants reported that the duration of hair loss was up to 6 months, and hair regrowth was noticed within 1 year after COVID-19 development. Patients who were admitted to the hospital, who experienced respiratory difficulties, who had lost weight due to COVID-19, and who experienced symptoms for longer than 10 days were significantly more prone to experience severe hair loss following COVID-19 (P < 0.001). Conclusion(s): This study demonstrated a high frequency of self-reported hair loss after the development of COVID-19. Interestingly, even patients with mild COVID-19 symptoms were significantly more prone to experience moderate hair loss. Unique to COVID-19 infection, the onset of hair loss following the development of COVID-19 was within 3 weeks in one-third of the participants. Copyright © 2022 Hospital for Skin Diseases.
ABSTRACT
BACKGROUND: Acute telogen effluvium is a non-scaring hair loss, usually occurs 3 months after the stressful event that causes hair shedding, and lasts up to 6 months. It can be associated with post COVID-19 infection. OBJECTIVE: To study the possible effects of COVID-19 on the hair growth cycle and the relationship between COVID-19 and acute telogen effluvium. PATIENTS AND METHODS: This is an observational cross-sectional study that had been conducted during the period from September 2020 to March 2021 years. Thirty-nine patients with post COVID-19 hair loss are confirmed by polymerase chain reaction (PCR) or antibody testing. Hair pull test was carried out to confirm the diagnosis and severity of telogen effluvium. RESULTS: Thirty-nine patients were evaluated; their ages ranged from 22 to 67 years with a mean and SD of 41.3 ± 11.6 years with 36 (92.3%) females and 3 (7.69%) males. All patients with a diagnosis of ATE were enrolled in this study and had a laboratory-confirmed diagnosis of prior SARS-CoV-2 infection; 15 (38.46%) patients reported mild symptoms, 24 (61.53%) patients presented with moderate disease, and no patient required hospitalization. They all experienced excessive hair loss within 2-3 months after infection. Pull tests were strongly positive (> 10-50% with a mean of 35% of pulled hair away from scalp). CONCLUSION: COVID-19 infection is now a frequent and a common cause of acute telogen effluvium. Hence, clinicians should be aware about the relation between this infection and this pattern of hair loss. Drugs that have been used for the treatment of COVID-19 were excluded as a cause of acute telogen effluvium.
Subject(s)
Alopecia Areata , COVID-19 , Acute Disease , Adult , Aged , COVID-19/complications , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , SARS-CoV-2 , Young AdultABSTRACT
Background: Telogen effluvium (TE) after COVID-19 infection or vaccination is a common sequelae in dermatology clinics. Objective(s): to study the prevalence of telogen effluvium in COVID-19 patients and its association with COVID vaccine. Method(s): Cross-sectional study via online questionnaire in Saudi Arabia and other Arabic countries. Result(s): Prevalence of hair loss among COVID-19 patients is ~85% with 45.9% meeting the criteria of TE. Majority of those with high fever associated with COVID-19 developed TE (87.5%). 100% of hospitalized patients exhibited TE with 58% having diffuse hair loss for less than 6 months (acute TE) and 32% for more than 6 months (chronic TE). 63.2% of our participants had hair loss after COVID vaccination regardless of vaccine type with the majority experiencing it after the first dose (55.8%). Limitation(s): The majority of the participants were female. Other factors associated with hair loss were taken into consideration. Conclusion(s): COVID-19 infection and its vaccines carry a high risk for development of telogen effluvium. Copyright © 2022 Ubiquity Press. All rights reserved.
ABSTRACT
Background: Number of reports linked Telogen effluvium to coronavirus disease 2019 (COVID-19) infection. However, data about Telogen effluvium after COVID-19 vaccination are limited. Objectives: To estimate prevalence of Telogen effluvium among those who received COVID-19 vaccination. Methods: A cross-sectional study was performed during July 2021. Adults who received one of recognized COVID-19 vaccine irrespective of previous COVID-19 infection were asked to fill a questionnaire. Results: The majority of participants were females (90.3%). The most common age group was between 21 and 30 years (51.9%). Out of 991 participants who were included in the current analysis, 670 (67.6%) reported post-vaccination hair fall. The probable causes of post-vaccination hair fall were vaccine-related in 185 (27.6%) participants, other causes in 326 (48.7%) participants, and unclear in 326 (48.7%) participants. Post-vaccination hair fall was significantly higher among females compared with males (68.5% versus 57.9%, P = 0.036), those who did not suffer compared with those who suffered from hair fall before vaccination (72.1% versus 63.4%, P = 0.003), and those who did not report compared with those who reported preexisting conditions that might be related to hair fall (74.5% versus 57.3%, P < 0.001). Conclusion: We are reporting a high prevalence of post-vaccination hair fall, which affected approximately two-thirds of participants who received COVID-19 vaccines. Only 28% of these participants were apparently vaccine related. The role of COVID-19 infection and stress caused by infection and vaccine cannot be excluded. Primary care physician and dermatologist need to consider the possibility of COVID-19 vaccine as a potential cause of hair loss.
ABSTRACT
Background Coronavirus disease 2019 (COVID-19) is an infectious disease that is associated with many health conditions, including, but not limited to, dermatological diseases. Some patients suffer from hair loss after becoming infected with severe acute respiratory syndrome coronavirus 2. Acute telogen effluvium (TE) is a non-scarring hair loss that usually occurs three months after a stressful event and can last up to six months, and it can be associated with post-COVID-19 infections. This study aims to explore the prevalence of hair loss among recovered COVID-19 patients in Saudi Arabia and determine the contributing factors. Furthermore, we aimed to measure the impact of hair loss after COVID-19 on their quality of life. Methodology An observational, cross-sectional study was conducted from September to December 2021 in Saudi Arabia. A questionnaire was used to assess hair loss after being infected with COVID-19. Furthermore, quality of life was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. Participants were recruited by sharing the questionnaire on social media platforms (Twitter, Telegram, and WhatsApp). The data were analyzed using SPSS version 23 (IBM Corp., Armonk, NY, USA). Frequency and percentages were used to display categorical variables, while minimum, maximum, mean, and standard deviation were used to present continuous variables. The categorical variables were compared using a chi-square test, and the statistical significance cut-off was set at p < 0.05. Results A total of 806 participants were included in the study, of whom 52.7% experienced hair loss after COVID-19 infection. Age, gender, high temperature during, and the presence of hair loss prior to infection were significantly associated with the incidence of TE. The severity of life affection based on DLQI showed that 91.4% of the participants did not have severe life affection, while 8.6% had their lives severely affected. Conclusions This study revealed subjective hair loss that was significantly associated with high temperature, being female, and having a history of previous hair loss. Further studies using objective assessments are suggested for reaching more precise conclusions.
ABSTRACT
Introduction COVID-19, caused by SARS-CoV-2, is a worldwide pandemic with the most main symptoms seeming to be flu-like and fever. Besides that, dermatological manifestations have been reported as extra respiratory symptoms in previous studies. The aim of this study is to measure the prevalence of hair loss after COVID-19 infection in Saudi Arabia, and we hope to improve the knowledge on hair loss - a cause of common dermatological consultation that frequently becomes a stressful event associated with the pandemic - among all the physicians in all the specialties. Methodology This was a record-based retrospective cross-sectional, multicenter study conducted in four centers in the Makkah region. We identified 343 patients who visited the dermatology clinic for hair loss during the period 2020 to 2022. Results Evidence suggests that hair loss had been the most frequently reported post COVID-19 manifestation (48%). Our results revealed nearly half of the participants (48.5%) noticed hair loss increases by more than 120 hairs per day after COVID-19 infection, as well as half of the participants (52.6%) reported seeing hair accumulation on a pillow. Our results showed that telogen effluvium (TE) was the most reported type (156, 86.7%), followed by alopecia areata (15, 8.3%) and androgenic alopecia (9, 5.0%). Conclusion The results suggest that hair loss is noticeably prevalent in patients following COVID-19 infection, especially in females and patients with multiple comorbidities. Telogen effluvium (TE) was the most prevalent type of hair loss recognized among the patients.
ABSTRACT
People affected with severe acute respiratory syndrome coronavirus 2 can have a wide variety of symptoms. Literature and public discussion forums report persistent symptoms among COVID-19 survivors. More than 25% of COVID-19 survivors report hair loss as a persisting issue. The Centers for Disease Control and Prevention state that hair loss as a potential long-term effect of COVID-19 is currently under investigation. This report may be the first case of hair loss in the patient with postCOVID-19 infection in Saudi Arabia.
ABSTRACT
Introduction: Telogen effluvium (TE) is characterized by diffuse hair shedding 2-3 months after a stressor, and factors such as hypoxia, inflammation (interleukin 6), medications and need for mechanical ventilation may play a role in the development and severity of TE caused by COVID-19. Aims: Evaluate the benefit of the hair care routine using products containing active ingredients to reduce the microinflammation of the scalp and increase the resistance of the hair strand to treat subjects with TE caused by COVID-19. Case presentation: After 60 days of the hospitalization due to COVID-19 infection, a 58-year-old woman showed a typical diagnostic of TE associated to post–COVID-19 infection, presenting positive results to traction test, trichoscopy, and trichogram. During 30 days, she used: 1) Product A: shampoo containing Aminexil, niacinamide, pyridoxine and panthenol;2) Product B: conditionate containing SP94 (glucose + linoleic acid);and 3) Product C: treatment ampoules containing creatine, panthenol, and ceramide R. The products A plus B were used once time for daily and the product C was used 3 times a week. Results: After the treatment, the subject presented an improvement of 100% of the hair loss, with negative results to traction test, trichoscopy, and trichogram analysis. The subject reported a high satisfaction with the treatment (ratio 10/10). Discussion: The hair care routine using the products A, B, and C could improve the TE caused by COVID-19, maybe by reduction inflammatory process in the scalp. Clinical studies in the high scale must be conducted to proof this hypothesis.
ABSTRACT
Introduction: COVID-19 infection is a disease caused by the type 2 coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2) that affects the respiratory mucosa and all those organs that present the type 2 angiotensin receptor (ACE2), within them the skin. Several authors have mentioned the importance of reporting and carrying out databases on skin lesions caused by this virus, since it is related to the detection, severity and prognosis of the systemic condition. Material and methods: A retrospective cross-sectional observational study was carried out on the cases of patients who presented dermatological manifestations due to COVID-19, registered in the physical database of the National Specialized Hospital of Villa Nueva, Guatemala, from January 1st to December 31, 2021. Results: A total of 144 patients presented dermatological manifestations due to COVID-19, which were: acral lesions (42%), rash (21%), subcutaneous emphysema (12%), oral mucosal lesions (7%), necrosis (6%), erythema multiforme (5%), telogen effluvium (2%), vesicular lesions (2%), urticaria (1%), pityriasis rosea Gibert (1%) and livedo-type lesion (1%). A statistically significant association (p = 0,00) was found in patients who presented dermatological manifestations with vasculonecrotic damage as they were more likely to suffer from severe to critical disease (OR 2,91;95% CI 1063-3083). Conclusions: Early identification of cutaneous semiology is essential for timely management of complications associated with COVID-19 disease.
ABSTRACT
Background Since being declared a pandemic, Coronavirus Disease 19 (COVID-19) has spread worldwide and causes various manifestations, including hair symptoms. Infection with COVID-19 produces inflammation and stress, which results in dermatological symptoms affecting the skin and hair. The most common hair loss-related finding in COVID-19 instances is Telogen Effluvium (TE), which is characterized by widespread non-scarring hair loss. The hair shedding that occurs usually happens two to three months after infection. In this article, we review and summarize how hair loss was induced in COVID-19 infections, how TE and COVID-19 severity is associated, as well as the duration and onset of TE following COVID-19 infections. Methods A literature search through PubMed was performed and nine studies were found. Studies included case reports and case series published from 2020 to 2021. Results From the nine studies reviewed, we found more than 50% of females suffered from post-COVID TE, with an age range of 20-76 years old and a mean age of 42.89 years old. The average number of days to TE onset was ±63 days after COVID-19 infection. TE was discovered in patients with mild to moderate COVID-19. Several studies have found that Caucasians are more likely to suffer from TE compared to other racial groups. The comorbidities in most of the patients included vitamin D deficiency, anemia, hypothyroidism, and type 2 diabetes mellitus. Conclusion Various factors influence post-COVID TE, including age, time of onset, gender, severity of COVID-19 infection, and pre-existing comorbidities (vitamin D deficiency, anemia, hypothyroidism, and type 2 diabetes mellitus).
Subject(s)
COVID-19 , COVID-19/epidemiology , COVID-19 Testing , Humans , New York City/epidemiology , Pandemics , Safety-net ProvidersABSTRACT
The diffusion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inducing coronavirus disease 2019 (COVID-19) has increased the incidence of several dermatological disorders, including hair loss (HL). This article aims to review the literature regarding the incidence of HL and telogen effluvium (TE) in COVID-19 patients and critically appraise the available evidence regarding the role of regenerative strategies like Platelet-Rich Plasma (PRP) and Human Follicle Stem Cells (HFSCs). A literature review regarding the correlation of HL and TE in COVID-19 patients analyzing the biomolecular pathway involved and the role of regenerative strategies was performed using PubMed, MEDLINE, Embase, PreMEDLINE, Scopus, and the Cochrane databases. Observational studies revealed an escalated incidence of pattern HL and TE in COVID-19 patients. Psychological stress, systemic inflammation, and oxidative stress are potential culprits. Proinflammatory cytokines and stress hormones negatively affect the normal metabolism of proteoglycans. Reduced anagenic expression of proteoglycans is a potential mediating mechanism that connects HL to COVID-19. Currently, only one study has been published on PRP against HL in COVID-19 patients. Further controlled trials are required to confirm PRP and HFSCs efficacy in COVID-19 patients.
Subject(s)
Alopecia Areata , Alopecia , COVID-19 , Mesenchymal Stem Cells , Platelet-Rich Plasma , Alopecia/therapy , Alopecia/virology , Alopecia Areata/therapy , Alopecia Areata/virology , COVID-19/complications , COVID-19/therapy , Humans , Proteoglycans , SARS-CoV-2ABSTRACT
Various conditions, including infections, can cause telogen effluvium (TE). One of them is coronavirus disease 2019 (COVID-19), where hair loss usually begins between 2 and 12 weeks after the illness. TE can be acute or chronic, and the chronic type can be intermittent. Here, we present the case of a 17-year-old girl with severe and widespread hair loss following an upper respiratory infection suspected to be COVID-19, with the patient having a history of such attacks since childhood. Evidence from biopsy and dermoscopy indicated a diagnosis of TE.
ABSTRACT
Introduction: Corona virus disease has several dermatological symptoms. Telogen effluvium is one of them. The present study presents a case series of post COVID Telogen effluvium from Central India region. Material and Method: This retrospective observational study included 72 patients (61 females & 11males), aged 29 to 62 years (median 49 yrs). The patient’s demography, history of hair fall, signs and symptoms, co morbidities and the treatment received for COVID-19 infection, Psychological perceived stress score, triggering factors for Telogen effluvium, Vitamin B12, Vitamin D and Ferritin levels were recorded & analysed. Result: The included patients were suffering from at least one co morbidity. Thirty patients had severe COVID-19 infection and were hospitalized. Psychological perceived stress score was low (12) in two, moderate (16-24) in twenty and high (29-38) in fifty patients. Vitamin B12 was low in twelve and Ferritin in ten patients. Seventy patients (97.2%) had positive hair pull test and 69 (95.8 %) had diffuse loss of hair. Discussion: Post covid Telogen effluvium was seen generally in females, and in middle aged. Most, 70/72 had moderate to severe psychological stress, Psychological perceived stress score was more than 16. Patients reported 2.2 to 6 months (median 3.5 months) after COVID-19 infection. Most 69 (95.8%) had diffuse hair loss. Post Covid patients may have several triggering factors for Telogen effluvium like psychological stress, nutritional deficiency or the drugs (heparin). Conclusion: Post Covid Telogen effluvium could be triggered by psychological stress, nutritional deficiencies (Vitamin B12, Iron) or drugs (heparin). Such cases could be managed by identification of triggering factors, proper counselling, high protein diet with vitamin supplementation.
ABSTRACT
Introduction: Psychological stress from the ongoing coronavirus disease 2019 (COVID-19) pandemic can potentially aggravate the course of several stress-sensitive skin and hair diseases. This study aimed to determine the potential association of COVID-19 stress with hair diseases, such as telogen effluvium (TE), alopecia areata (AA), and seborrheic dermatitis (SD), among medical students in Bangladesh. Methods: This online-based cross-sectional study was conducted among 404 medical students of Bangladesh using a self-administered questionnaire, including sociodemographic information, status of hair diseases (i.e., TE, AA, and SD), COVID-19 fear scale, impact of event scale specific for COVID-19 (IES-COVID-19), and COVID-19 student stress questionnaire (CSSQ) scale, to determine pandemic-related stress. The logistic regression model was used to analyze the association. Results: Overall prevalence of TE, AA, and SD was 61.1, 24.7, and 57.7%, respectively, with female predominance in case of TE and male predominance in case of AA and SD. More than half of the participants had COVID-19-related fear and traumatic stress symptoms. In the multiple logistic regression model, smoking [adjusted odds ratio (aOR) 2.93, 95% CI 1.29-6.65 for AA and aOR 4.19, 95% CI 1.83-9.56 for TE], COVID-19-related fear (aOR 1.70, 95% CI 1.01-2.89 for AA and aOR 2.620, 95% CI 1.25-5.48 for TE), and COVID-19-related traumatic stress symptoms (aOR 1.84, 95% CI 1.08-3.13 for AA, aOR 2.61, 95% CI 1.19-5.68 for TE, and aOR 1.92, 95% CI 1.14-3.25 for SD) were the risk factors of hair fall disorders. Conclusion: Our study showed that a large number of medical students experienced TE, AA, and SD during the pandemic era. COVID-19-related stress and fear potentially have an association with these diseases.
ABSTRACT
COVID-19 is a concerning global pandemic. Common manifestations are fever and respiratory symptoms. In addition, recent studies reported dermatological manifestations as extrapulmonary signs. One of these is telogen effluvium which is related to post COVID-19 comorbidities. The aim of this study was to assess the prevalence of telogen effluvium among COVID-19 patients. This observational cross-sectional study included 198 patients who were admitted for COVID-19. The PCR test was performed to detect positive cases. After discharge, all patients were interviewed about hair loss. Of these patients, 79 were male (39.9%), and 119 were female (60.1%). The age ranged from 18 to 85 years old. 48 patients showed hair loss. Telogen effluvium (TE) is one of the consequences of the COVID-19 pandemic. COVID-19 leads to more medications and stress situations, which trigger TE.